SMA UK, MDUK and TreatSMA send joint letters to NICE, Biogen and NHS England

29 November 2018

As an act of ‘good faith’ in their commitment to progress discussions to a satisfactory conclusion, we urge all three parties to agree, with immediate effect, to implement a ‘bridging solution’ for access to nusinersen for any infants with SMA Type 1.

Read the letter to Biogen

Read the letter to NICE

Read the letter to NHS England